Teva Pharmaceutical Industries Limited (NYSE:TEVA) Position Increased by Ethic Inc.

Ethic Inc. increased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 45.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 55,323 shares of the company's stock after acquiring an additional 17,267 shares during the period. Ethic Inc.'s holdings in Teva Pharmaceutical Industries were worth $1,219,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of TEVA. Oarsman Capital Inc. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $44,000. Ameliora Wealth Management Ltd. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $66,000. IFP Advisors Inc lifted its position in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after buying an additional 1,960 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its position in Teva Pharmaceutical Industries by 27.7% during the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after buying an additional 949 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Up 0.5%

Shares of NYSE:TEVA traded up $0.08 during midday trading on Friday, reaching $16.95. The company had a trading volume of 9,758,609 shares, compared to its average volume of 9,995,809. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The stock's fifty day moving average price is $15.34 and its 200-day moving average price is $17.43. The stock has a market capitalization of $19.22 billion, a P/E ratio of -11.69, a PEG ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business's revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.48 earnings per share. Equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Barclays reduced their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $24.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.